Skip to main content
. 2020 Dec 13;14(2):100961. doi: 10.1016/j.tranon.2020.100961

Fig. 1.

Fig. 1

BEBT-109 structure and its selectivity profile. A, Chemical structure of BEBT-109. B, EGFR binding assay was performed to determine the selectivity and potency of BEBT-109 (n = 2). C,In vitro pharmacologic profiling assay was used to assess the potential off-target effects of BEBT-109 (10 μmol/L) against major targets. Graph represents mean percent response+SEM. Values less than 75% (indicated by dashed lines) were considered nonsignificant zone (n = 2). D, Kinase affinities of BEBT-109 against CHRM1, INSR, VEGFR2 and HTR2A were determined by kinase binding and PathHunter β-arrestin assay (n = 2).